Project Details
Description
A Phase 1, Open-label, Dose-escalation trial of CD33xCD3 Bispecific Antibody in Pediatric patients with Relapsed or Refractory Acute Myeloid Leukemia
| Status | Finished |
|---|---|
| Effective start/end date | 9/1/21 → 8/31/24 |
Funding
- PUBLIC HEALTH INSTITUTE
- Y-MABS THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.